Ethical Approval Secured for Glucotrack's Clinical Study
Glucotrack, Inc. (NASDAQ: GCTK) has made a significant step in diabetes management by obtaining ethical clearance from the St. Vincent’s Hospital Melbourne Human Research Ethics Committee for its comprehensive clinical study. This innovative study focuses on the long-term use of the Company’s continuous blood glucose monitor (CBGM) in individuals managing type 1 and type 2 diabetes.
Study Overview and Objectives
The long-term, prospective, single-arm, multi-center study aims to recruit up to 30 participants suffering from diabetes mellitus who require consistent glucose monitoring and intensive insulin therapy. Over an initial assessment period of one year, the study will analyze the performance and safety of Glucotrack’s device. The Company plans to submit additional documentation to extend the study's duration to three years following the initial evaluation.
Regulatory Process Following Approval
Now that ethical approval has been granted, Glucotrack will communicate with the Therapeutic Goods Administration (TGA) of Australia, responsible for regulating therapeutic goods, prior to enrolling participants. The commencement of the study is anticipated, with the first implantations expected to take place in July.
Leading Expert Involved in the Study
Distinguished researchers will guide the study under the leadership of Professor David O’Neal, the Director and Founder of the Diabetes Technology Research Group at the University of Melbourne. He will be joined by Associate Professor Neale Cohen from the Baker Heart and Diabetes Institute. Professor O’Neal expressed his enthusiasm regarding the study, stating, "This technology could significantly improve glycemic control, providing diabetes patients with a greater selection in continuous glucose monitoring systems." He highlighted that the potential of measuring blood glucose directly offers a transformational improvement over traditional methods that rely on interstitial fluid measurements.
Innovative Features of Glucotrack’s CBGM
Glucotrack’s CBGM system is designed to ensure user comfort and accuracy by being a long-term implantable device. Unlike conventional glucose monitors that require users to wear an external device, this innovative system provides seamless monitoring for up to three years with minimal calibration needed. Additionally, by directly measuring glucose levels in the blood, it aims to offer real-time insights with reduced lag time compared to previous interstitial fluid methods.
Comments from Leadership
Highlighting the importance of this achievement for Glucotrack, Dr. Paul V. Goode, President and CEO, remarked, "This milestone underscores our commitment to our clinical program and builds on our previous successful trials. Collaborating with leading experts like Professor O’Neal will provide essential information regarding the long-term safety and efficacy of our CBGM system. Taking into account patient feedback, we aim to solve critical challenges in diabetes monitoring, such as sensor lifespan and the removal of on-body components."
Focused on Diabetes Innovation
Glucotrack, Inc. (NASDAQ: GCTK) continues to focus on developing advanced technologies for diabetes care. The CBGM system, with its long-lasting sensor capability and minimal use of external worn devices, promises to deliver a more user-friendly experience for individuals managing diabetes. As the study progresses, anticipation grows regarding the insights it will bring to enhance the lives of those living with diabetes.
Frequently Asked Questions
What is Glucotrack's latest clinical study about?
Glucotrack's latest study focuses on evaluating the long-term performance and safety of its continuous blood glucose monitor for type 1 and type 2 diabetes patients.
How many participants will be enrolled in the study?
The study plans to enroll up to 30 participants who require glucose monitoring as part of their diabetes management.
What is unique about Glucotrack’s glucose monitoring system?
The CBGM measures blood glucose directly, unlike traditional systems that use interstitial fluid, providing real-time and more accurate glucose readings.
When is the expected start date for patient enrollment?
The first implants of the device are expected to begin in July, following the necessary regulatory notifications.
Who is overseeing this clinical trial?
The study will be led by Professor David O’Neal and Associate Professor Neale Cohen, regarded experts in diabetes technology research.
